This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

DaVita To Present Twelve Posters And One Oral Presentation At American Society Of Nephrology Kidney Week

Stocks in this article: DVA

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), will present 13 abstracts at the American Society of Nephrology (ASN) Kidney Week in San Diego, November 1-4. Attendees can find DaVita® representatives in booth #1903.

ASN’s annual Kidney Week provides a valuable opportunity for more than 13,000 kidney care professionals from around the world to share and discuss new developments related to all aspects of nephrology.

“Our goal at DaVita – in collaboration with our partners – is to advance the knowledge and practice of kidney care,” said DaVita Vice President of DaVita Clinical Research® Mahesh Krishnan. “The work we will share at ASN will, we hope, lead to better clinical outcomes and better quality of life for CKD and end-stage renal disease patients around the world.”

Researchers from DaVita and DaVita Clinical Research (DCR®) will present results from a number of innovative clinical improvement programs and health economic studies originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita services and the academic, pharmaceutical, and biotech research community. DCR shares DaVita’s dedication to improving the health and quality of life for kidney patients.

ASN Kidney Week abstract highlights include the following:

  • Extracellular Volume Control in Dialysis Patients To Reduce Hospitalizations (oral presentation FR-OR026 of joint study between DaVita, Fresenius Medical Care, and Renal Ventures, LLL; to be presented by Thomas Parker, M.D., Renal Ventures Management, LLC)
  • Analysis of the 2014 Quality Improvement Program Reporting Measures for Calcium Phosphate in Dialysis Patients (Nissenson et al, abstract SA-PO268)
  • Hemoglobin Trends in Incident End-Stage Renal Disease (ESRD) Patients from 2008-2011 (Weldon et al, abstract FR-PO222)
  • Changing Hemoglobin Targets: Effects on Epoetin Alfa, Intravenous Iron, and Iron Storage Measures From 2009–2012 (Bond et al, abstract TH-PO822)
  • A Comparative Analysis of Transfusion Trends between Types of Providers of Dialysis Services Using Medicare Claims Data (Krishnan et al, abstract FR-PO263)

DaVita, DaVita Clinical Research and DCR registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,588.18 +231.31 1.33%
S&P 500 2,040.08 +27.19 1.35%
NASDAQ 4,709.6520 +65.34 1.41%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs